BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miroshnychenko KV, Shestopalova AV. Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: the results of a molecular simulation study. J Biomol Struct Dyn 2022;40:8672-86. [PMID: 33896392 DOI: 10.1080/07391102.2021.1914168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Frota LS, Alves DR, Marinho MM, da Silva LP, Almeida Neto FWQ, Marinho ES, de Morais SM. Antioxidant and anticholinesterase activities of amentoflavone isolated from Ouratea fieldingiana (Gardner) Engl. through in vitro and chemical-quantum studies. J Biomol Struct Dyn 2023;41:1206-16. [PMID: 34907850 DOI: 10.1080/07391102.2021.2017353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gao K, Wang R, Chen J, Cheng L, Frishcosy J, Huzumi Y, Qiu Y, Schluckbier T, Wei X, Wei GW. Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2. Chem Rev 2022;122:11287-368. [PMID: 35594413 DOI: 10.1021/acs.chemrev.1c00965] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
3 Das T, Mukhopadhyay C. Computational studies suggest compounds restoring function of p53 cancer mutants can bind SARS-CoV-2 spike protein. J Biomol Struct Dyn 2022;:1-14. [PMID: 35333136 DOI: 10.1080/07391102.2022.2048081] [Reference Citation Analysis]
4 Xiong X, Tang N, Lai X, Zhang J, Wen W, Li X, Li A, Wu Y, Liu Z. Insights Into Amentoflavone: A Natural Multifunctional Biflavonoid. Front Pharmacol 2021;12:768708. [PMID: 35002708 DOI: 10.3389/fphar.2021.768708] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
5 Ahmad I, Pawara R, Surana S, Patel H. The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19. Top Curr Chem (Cham) 2021;379:40. [PMID: 34623536 DOI: 10.1007/s41061-021-00353-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
6 Mahmoud A, Mostafa A, Al-Karmalawy AA, Zidan A, Abulkhair HS, Mahmoud SH, Shehata M, Elhefnawi MM, Ali MA. Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies. Heliyon 2021;7:e07962. [PMID: 34518806 DOI: 10.1016/j.heliyon.2021.e07962] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 21.0] [Reference Citation Analysis]
7 Binette V, Côté S, Haddad M, Nguyen PT, Bélanger S, Bourgault S, Ramassamy C, Gaudreault R, Mousseau N. Corilagin and 1,3,6-Tri-O-galloy-β-D-glucose: potential inhibitors of SARS-CoV-2 variants. Phys Chem Chem Phys 2021;23:14873-88. [PMID: 34223589 DOI: 10.1039/d1cp01790j] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Pinto GP, Vavra O, Marques SM, Filipovic J, Bednar D, Damborsky J. Screening of world approved drugs against highly dynamical spike glycoprotein of SARS-CoV-2 using CaverDock and machine learning. Comput Struct Biotechnol J 2021;19:3187-97. [PMID: 34104357 DOI: 10.1016/j.csbj.2021.05.043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Mahdian S, Zarrabi M, Panahi Y, Dabbagh S. Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations. Inform Med Unlocked 2021;23:100541. [PMID: 33649734 DOI: 10.1016/j.imu.2021.100541] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]